The news indicates a strategic focus on the most promising therapies, which could lead to efficient use of resources and potentially successful outcomes. This strategic prioritization is generally viewed positively by investors as it may enhance the company's prospects for future revenue and growth. However, without specific details on the clinical trials or regulatory milestones, the impact is somewhat speculative.